Clinical trials: Oral Phase
Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
To evaluate the safety and tolerability of escalating, single subcutaneous doses of MEDI7734 in adult subjects with type I interferon-mediated autoimmune diseases.
- Trial name
- NCT02780674
- Testing
- MEDI7734
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Amgen
Type 2 Diabetes
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
This is an intervention, phase IV, single-arm study to assess the safety and efficacy of iGlarLixi in adult patients with Type 2 diabetes.
- Trial name
- NCT06716424
- Testing
- iGlarLixi (insulin glargine/lixisenatide)
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Sanofi
Trigeminal Neuralgia
802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with trigeminal neuralgia (TN).
- Trial name
- SURGE-1 (NCT03070132)
- Testing
- BIIB074
- Sponsor
- Biogen
Healthy
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
The purpose of this study is to understand if ARV-471 affects how a medicine called, dabigatran etexilate, gets absorbed or processed into the body in healthy adults.
- Trial name
- NCT05673889
- Testing
- ARV-471, Dabigatran etexilate
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sjögren´s Disease
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
The purpose of this study is to demonstrate the efficacy and safety of ianalumab (VAY736) 300 mg administered subcutaneously (s.c.) monthly for 52 weeks in adult participants with Sjögren's disease who have high symptom burden.
- Trial name
- THALASSA (NCT07621809)
- Testing
- VAY736
- Where
- 33 sites in United States, Australia and 6 more
- Volunteers
- 570 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Infections
A Single Dose Study of Debio 1450 in Healthy Subjects
The sponsor is trying to develop a medicine for infections that are not cured by regular antibiotics. They have an experimental drug called Debio 1450 that may work. They need about 48 healthy adults to volunteer for this study.
- Trial name
- NCT02162199
- Testing
- Debio 1450
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Debiopharm International SA
Healthy Participants
A Study of Qishenyiqi Dripping Pills in Healthy Participants
This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.
- Trial name
- NCT04471298
- Testing
- Qishenyiqi dripping pills, 6 bags, Qishenyiqi dripping pills, 9 bags, Qishenyiqi dripping pills, 12 bags
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Non Small Cell Lung Cancer, Cancer
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression
Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.
- Trial name
- NCT04274907
- Testing
- Venetoclax, Pembrolizumab
- Where
- 39 sites in United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
Carcinoma, Advanced Cancer
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
TRX-818 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. TRX-818 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT02507544
- Testing
- TRX-818 capsules
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- TaiRx, Inc.
Dyslipidemia
Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519
The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519.
- Trial name
- CKD-519 FIH (NCT02156544)
- Testing
- CKD-519
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hen Egg Allergy
Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
- Trial name
- NCT04056299
- Testing
- AR201 powder
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aimmune Therapeutics, Inc.
Arrhythmias, Cardiac, Heart Diseases
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
This study will evaluate the efficacy and safety of Azimilide on the incidence of cardiovascular hospitalizations, cardiovascular emergency department visits or cardiovascular death in patients with Implantable Cardioverter…
- Conditions
- Arrhythmias, Cardiac, Heart Diseases, Cardiovascular Diseases, Implantable Cardioverter Defibrillator
- Trial name
- SHIELD-2 (NCT01464476)
- Testing
- Azimilide Dihydrochloride
- Where
- 138 sites in United States, Belgium and 11 more
- Volunteers
- 240 people
- Sponsor
- Forest Laboratories
Atopic Dermatitis
Oral DS107 in Moderate to Severe Atopic Dermatitis
This study will compare the safety and efficacy of Oral DS107 (2 g) to placebo in patients with moderate to severe atopic dermatitis. Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo.
- Trial name
- NCT02211417
- Testing
- Oral DS107
- Where
- 14 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Dignity Sciences Ltd.
Migraine
Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds
Study Objectives: 1. The primary objective is to characterize the pharmacokinetics of a single oral administration of 50 mg Cambia in pediatric subjects, ages 12-17 years with a diagnosis of episodic migraine with or without…
- Trial name
- NCT02287376
- Testing
- Diclofenac Potassium for Oral Solution
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Depomed
Ulcerative Colitis
Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)
Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis.
- Trial name
- NCT04583358
- Testing
- AMT-101 (oral)
- Where
- 59 sites in United States, Belarus and 12 more
- Volunteers
- 105 people
- Sponsor
- Applied Molecular Transport
Myelodysplastic Syndrome (MDS)
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01459159
- Testing
- ezatiostat hydrochloride (Telintra®)
- Where
- 7 sites in United States
- Volunteers
- 162 people
- Sponsor
- Telik
Healthy
A Study of Oral YUQ-A1007 in Healthy Volunteers
YUQ-A1007 is a novel gut-enriched AhR agonist. The nonclinical pharmacology study indicated that YUQ-A1007 has the potential to treat IBD. YUQ-A1007 has not been evaluated in human clinical studies.
- Trial name
- NCT06835296
- Testing
- YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Healthy Subjects
A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of PF-06427878 in healthy adult…
- Trial name
- NCT02391623
- Testing
- PF-06427878
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Schizophrenia
Study to Asses Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AZD0328 in Patients With Schizophrenia
This study is to assess the pharmacodynamics, pharmacokinetics, safety and tolerability of multiple ascending doses of AZD0328 in patients with schizophrenia
- Trial name
- NCT00669903
- Testing
- AZD0328
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
HIV Infections
A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus.
- Trial name
- NCT00004583
- Testing
- Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 660 people
- Sponsor
- Abbott
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.